New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
16:12 EDTXOMAXOMA says Phase 3 PATH trial meets primary endpoint
XOMA announced the 837-patient Phase 3 PATH trial of perindopril arginine combined with amlodipine besylate is statistically significantly superior to either compound alone in reducing both sitting diastolic and sitting systolic blood pressure after six weeks of treatment. This FDC, containing a patent-protected proprietary form of perindopril, was licensed by XOMA as part of a U.S. commercial and development rights agreement signed with Servier for their perindopril franchise. Servier markets the fixed-dose combination product, COVERAM, in 91 countries outside the U.S. The FDC appeared to be well tolerated in the trial, and there were no unexpected serious adverse events reported. The most common adverse events included mild to moderate edema, cough and headache, which are known side effects of the individual components of the FDC, the company said.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
08:13 EDTXOMACapital Ventures reports 6.3% passive stake in XOMA
Subscribe for More Information
December 9, 2014
09:09 EDTXOMAXOMA raises $40M in a registered direct offering
XOMA (XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. Cowen and Company is acting as the sole placement agent.
December 4, 2014
08:21 EDTXOMAXOMA March volatility elevated at 169
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use